Devices Expand Treatment Options for Migraine

article image

Migraine has historically been managed medically, but in the last three years, four device companies have entered the market. They hope to become first-line therapies for a two- to four- million patient slice of the multibillion-dollar migraine market. Part 2 of a 2-part article on devices for migraine.

While the COVID-19 pandemic has derailed the plans of many companies in 2020, the emerging device market for the treatment of migraine has reported much good news. This year brought FDA clearances for electroCore Inc., Cefaly Technology SPRL, and Theranica Bio-Electronics Ltd.; FDA’s Breakthrough Device Designation for Salvia BioElectronics BV; and hefty Series A investments for Salvia and ShiraTronics Inc.

These announcements have focused attention on unmet medical needs that exist for millions of migraine sufferers (36-40 million in the US alone) many of whom aren’t adequately helped by many choices of drugs constituting a $1.3 billion market that is growing by more than 13% (according to a January 2020 report published by research firm Reports and Data). 

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: